Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome by Jie, Kim E et al.
Short- and long-term effects of erythropoietin
treatment on endothelial progenitor cell levels in
patients with cardiorenal syndrome
Kim E Jie,
1 Karien van der Putten,
2,3 Marloes W T Bergevoet,
1 Pieter A Doevendans,
4
Carlo A J M Gaillard,
3,5 Branko Braam,
6 Marianne C Verhaar
1
ABSTRACT
Objective Patients with cardiorenal syndrome (CRS)
have high cardiovascular morbidity. Endothelial
progenitor cells (EPC) constitute an endogenous vascular
repairsystem, protecting against atherosclerosis
development. Erythropoietin (EPO) treatment may have
beneﬁcial effects by mobilizing EPC from the
bonemarrow. Our objective is to determine EPC levels
and effects of EPO therapy on EPC levels in CRS patients.
Design Open-label randomized trial.
Setting Part of the EPOCARES-trial, conducted in
Utrecht (Netherlands).
Patients Patients with CRS and anaemia and healthy
controls were included.
Interventions Patients were randomized to receive EPO
therapy (50 IU/kg/wk) for 52 weeks or no EPO therapy.
Main outcome measures CD34
+KDR
+-EPC, cultured
EPC outgrowth and function at baseline, after 18 days
and after 52 weeks.
Results Patients showed lower CD34
+KDR
+-cell
numbers compared to controls (6(12) vs. 19(19) cells/
10
5 granulocytes; p¼0.010), despite increased levels
of stromal cell-derived factor-1a; (3.1(0.8) vs 2.6(0.3)
ng/ml; p¼0.001). EPC outgrowth and function were not
different between patients and controls. EPC levels did
not change after 18 days with or without EPO treatment.
CD34
+KDR
+-cells signiﬁcantly declined after 52 weeks
in the non-treated group (p¼0.028). Long-term EPO
therapy did not signiﬁcantly affect this reduction in
CD34
+KDR
+-EPC levels.
Conclusions CRS patients showed reduced
CD34
+KDR
+-EPC levels compared to controls,
consistent with a reduced vascular regenerative
potential and despite upregulated SDF-1a levels.
Over a one-year follow-up period a marked 68% further
reduction in EPC levels was observed in the patient group
without EPO treatment. In spite of promising
experimental studies, our longitudinal, randomized
study did not show signiﬁcant inﬂuence of either short-
or long-term EPO therapy on reduced EPC levels in
CRS patients.
INTRODUCTION
Patients with the cardiorenal syndrome (CRS)die,
chronic heart failure (CHF) and chronic kidney
disease (CKD), often accompanied by anaemiad
have high cardiovascular morbidity and mortality.
1
Endothelial dysfunction and impaired endothelial
regenerative capacity play a key role in the patho-
genesis of atherosclerosic cardiovascular disease
(CVD). Bone marrow (BM) derived circulating
endothelial progenitor cells (EPC) constitute an
endogenous vascular repair system that may protect
against atherosclerosis development.
2 Reduced
EPC availability or function may contribute to the
pathogenesis of CVD.
Disease conditions with high cardiovascular risk,
including end-stage renal disease, have been asso-
ciated with reduced EPC levels and function.
3
Others have not observed such inverse relations or
even reported a positive relation between EPC
number and vascular risk factors.
4 In CHF, a nega-
tive correlation between cultured EPC and func-
tional New York Heart Association (NYHA) class
has been reported.
5 However, others have found
higher levels of EPC in mild CHF with increased
levels of EPC mobilising factors, whereas EPC in
severe disease were decreased, despite similar
increases in stromal cell-derived factor-1a (SDF-1a)
and vascular endothelial growth factor (VEGF).
67
This suggests a protective compensatory response
to the vascular risk burden in mild CHF, but
exhaustion or suppression of BM progenitor cells in
advanced CHF. We hypothesised that in CRS, the
combined presence of even mild stages of CHF,
CKD and anaemia is associated with impaired
levels of circulating EPC, due to accumulation of
uremic toxins, decreased nitric oxide availability
and increased inﬂammation.
Enhancing circulating EPC may enhance vascular
protection and reduce the progression of CVD.
Beneﬁcial effects of erythropoietin (EPO) on the
cardiovascular system have been suggested from
animal experiments
8 and small clinical studies
in patients with CKD
9 or CHF,
10 although these
could not be conﬁrmed in larger randomised
trials.
11 In patients with myocardial infarction,
circulating CD34
+ haematopoietic stem cells
(HSC) increased after single high-dose EPO injec-
tion.
8 Regular dose EPO treatment increased
EPC levels in advanced CKD
12 and improved
EPC function in CHF patients in the longer term.
13
No randomised controlled studies are available
on EPC and regular EPO dose effects in patients
with CRS. We hypothesised that EPO treatment
can improve EPC levels in CRS patients, which
may be related to a reduction in cardiovascular
risk.
We assessed circulating EPC levels and EPC
outgrowth number and function in CRS patients
compared to healthy controls, and evaluated
whether short-term (18 days) and long-term (52
weeks) EPO therapy improved EPC number and
function in patients with CRS.
< An additional table is
published online only. To view
this ﬁle please visit the journal
online (http://heart.bmj.com).
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Cardiorenal syndromeMETHODS
Study subjects
We studied a subgroup of CRS patients from the EpoCaReS trial
(ClinicalTrials.gov, NCT00356733), and healthy controls of
comparable age and gender. A detailed description with inclusion
and exclusion criteria of the study has previously been
published.
14 The protocol was approved by the medical ethics
committee and all patients gave informed consent. Procedures
were in accordance with the Helsinki Declaration.
Patients with mild anaemia (women: 6.4e7.4 mmol/l; men:
6.4e7.8 mmol/l), moderate CKD (estimated creatinine clearance
20e70 ml/min, CockcrofteGault formula) and CHF (functional
NYHA class IIeIV, based on symptoms, signs and objective
abnormality on echocardiography,
15 reduced ejection fraction
(<50%) or left ventricular end-diastolic volume index <97 ml/m
2
with evidence of diastolic left ventricular dysfunction
16) were
included.
Study design
EPC levels and function were compared between 45 CRS
patients at baseline and 20 healthy controls. The effects of EPO
treatment were evaluated in an open-label, randomised design.
Patients received EPO treatment (50 IU/kg/week; Neorecormon,
Roche Pharmaceuticals, Woerden, Netherlands) or standard
treatment without EPO for one year. Short-term effects of EPO
(n ¼30) versus no EPO (n ¼15) were evaluated after 18 days
(3 days after third EPO injection), when EPO treatment was not
yet expected to result in a haematopoietic response. Long-term
(52 week) effects of EPO were assessed in a subgroup of EPO-
treated patients, who were allowed to increase haemoglobin
(Hb) levels up to 8.5 mmol/l for men and 8.3 mmol/l for women
(n ¼13), and a non EPO-treated group (n ¼13).
Plasma measurements
Serum EPO levels were measured by sandwich chemilumines-
cent immunoassay (IMMULITE 2000 platform, Siemens
Healthcare Diagnostics, Breda, Netherlands). Endothelial
dysfunction, EPC mobilising factors and inﬂammation markers
were measured using ELISA (E-selectin, vascular cell adhesion
molecule-1 (VCAM-1), interleukin (IL)-6, VEGF, SDF-1a (R&D
Systems, Minneapolis, Minnesota, USA) and thrombomodulin
(Diaclone, Stamford, Connecticut, USA)) or multiplex immu-
noassay
17 (intercellular adhesion molecule-1 (ICAM-1) and
monocyte chemotactic protein-1 (MCP-1) (Bio-Rad Laboratories,
Hercules, California, USA)). High sensitivity C reactive protein
(hsCRP) was determined by particle-enhanced immunonephel-
ometry (standard Cardio-Phase hsCRP for BNII, Dade Behring
Holding, Liederbach, Germany). N-terminal prohormone of
brain natriuretic peptide (NT-proBNP) was measured using
electrochemiluminescense immunoassay (Cobas CA6000,
Roche, Mannheim, Germany). Samples were measured in
duplicate and averaged for analysis.
Circulating EPC levels
Circulating EPC were deﬁned as cells positive for haematopoietic
stem cell marker CD34 and endothelial marker kinase insert
domain receptor (KDR; ie, VEGF receptor-2). This CD34
+
KDR
+-EPC has previously shown clinical importance by
predicting cardiovascular events and death in cardiovascular risk
populations.
18 19 Blood (100 ml) was incubated with anti-CD34-
FITC (BD Pharmingen, California, USA), anti-KDR-PE (R&D
Systems) and anti-CD45-PE-Cy7 (BD Pharmingen) antibodies
for 45 min. Erythrocytes were lysed and analysed by ﬂow
cytometry (Beckman Coulter, California, USA). Circulating
HSC and EPC were identiﬁed as CD34
+ and CD34
+KDR
+ cells
in the lymphocyte region of the forward/sideward scatter plot.
Cell numbers were quantiﬁed relative to 10
5 granulocytes,
identiﬁed as CD45
+ cells with a typical granulocyte distribution.
Measurements were performed in duplicate and results were
averaged. Isotype-stained samples served as negative controls.
Outgrowth of EPC in culture
EPC outgrowth from mononuclear cells (MNC) was assessed as
described previously.
3 In brief, MNC were isolated from blood
using Ficoll density gradient separation (Histopaque 1077,
Sigma, St Louis, Missouri, USA). To evaluate EPC outgrowth in
culture, 10
7 MNC/well were seeded on a human ﬁbronectin
(Sigma) coated 6-well plate in EGM-2 (Cambrex, Baltimore,
Maryland, USA), supplemented with accompanying aliquots,
20% fetal calf serum (Invitrogen, Carlsbad, California, USA),
100 ng/ml recombinant VEGF-165 (R&D Systems) and antibi-
otics. Medium was changed after 4 days to wash non-adherent
cells away. After 7 days, cultured EPC in selected wells were
placed on serum free medium (EBM-2 with hEGF, hydrocorti-
sone, GA-1000, R
3-IGF-1, ascorbic acid, heparin and antibiotics)
overnight. Conditioned medium was stored for functional
experiments and cultured EPC were detached by trypsin and cell
scraping, and automatically counted using a haemocytometer.
In vitro scratch wound assay
The potential of EPC outgrowth to excrete paracrine factors that
stimulate endothelial cell migration was assessed by in vitro
scratch wound assay.
20 In brief, EPC outgrowth medium was
placed on a mechanically scratched conﬂuent human microvas-
cular endothelial cell layer. After 6 h, the extent of scratch
closure relative to the starting width was compared between
study groups using light photography. Each sample was
measured in two separate wells and two picture ﬁelds per well
were examined. Results were averaged for data analysis.
Statistical analysis
Data analysis was performed using SPSS V.15.0 for Windows.
Data distribution was tested by the KolmogoroveSmirnov
test. Data are expressed as mean 6 SD for parametric data
and as median (IQR) for non-parametric data. Differences
between groups were analysed using Student’s t test or the
ManneWhitney test. Fisher’s exact test was used to analyse
whether proportions of categories varied by group. Multiple
group comparisons were performed using ANOVA with LSD
post-hoc testing for which non-parametric data were log-trans-
formed. Correlations were measured by Pearson’s or Spearman’s
correlation coefﬁcient where appropriate. Multivariate determi-
nants of log-transformed progenitor cell counts were identiﬁed
by stepwise multiple linear regression analysis. A value of
p <0.05 was considered statistically signiﬁcant.
RESULTS
Baseline characteristics
Table 1 summarises baseline characteristics. Patients were mildly
anaemic, had reduced creatinine clearance, lower diastolic blood
pressure and reduced ejection fraction. CRS patients demon-
strated increased hsCRP levels and higher levels of markers for
endothelial dysfunction compared to healthy controls.
Haemoglobin levels during the study
Short-term EPO did not signiﬁcantly change Hb levels (7.5 (1.2)
vs 7.3 (1.0) mmol/l; p¼0.061), but signiﬁcantly increased reticu-
locyte count (0.06660.004 vs 0.04560.003310
12/l; p<0.001)
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Cardiorenal syndromecompared to baseline. Long-term EPO signiﬁcantly increased Hb
levels compared to baseline (8.4 (0.8) vs 6.9 (0.8) mmol/l;
p ¼0.012). Patients not treated with EPO remained anaemic at all
time-points (7.4 (0.4) baseline, 7.2 (0.8) 18 days, 7.4 (0.9) mmol/l
52 week; p-value not signiﬁcant between time-points).
Circulating EPC levels are reduced in CRS patients compared to
healthy controls
CD34
+KDR
+-EPC were 68% lower in CRS patients at baseline
compared to controls (ﬁgure 1A). CRS patients tended to have
lower CD34
+-HSC (38% reduction; ﬁgure 1B). No differences
were found in EPC outgrowth (ﬁgure 1C). In a scratch wound
assay, we observed no signiﬁcant difference between conditioned
medium from EPC outgrowth cultures from CRS patients and
controls for their capacity to stimulate endothelial cell migration
(ﬁgure 1D).
Univariate analysis revealed lower CD34
+KDR
+-EPC levels
in subjects with advanced age (r¼ 0.352; p¼0.007), lower Hb
(r¼0.362; p¼0.005) and estimated creatinine clearance (r¼0.328;
p¼0.012), and higher IL-6 levels (r¼ 0.302; p¼0.044) (supple-
mentarytable).CD34
+-HSCwerealsonegativelycorrelatedwith
age(r¼ 0.273;p¼0.038)andIL-6levels(r¼ 0.454;p¼0.002)and
tended to decrease in patients with lower estimated creatinine
clearance (r¼0.241; p¼0.068) and higher serum urea (r¼ 0.258;
p¼0.053). CD34
+-HSC were increased in patients with higher
plasma low density lipoprotein (LDL) (r¼0.285; p¼0.035).
After multivariate regression analysis of log-transformed
CD34
+KDR
+-EPC levels for age, Hb, estimated creatinine clear-
ance and IL-6, only Hb remained an independent predictor of
circulatingEPClevels(b¼0.323;95%CI0.021to0.538;p¼0.034).
OnlyIL-6(b¼ 0.443;95%CI 0.135to 0.029;p¼0.003)wasan
independent predictor of log-transformed CD34
+-HSC in multi-
variate regression analysis for age, IL-6 and plasma LDL levels.
No correlations were found for CD34
+- and CD34
+KDR
+-
cells with serum EPO levels. Presence of diabetes, statin use or
b-blockade treatment were not associated with circulating
Table 1 Baseline characteristics of study population
Healthy
controls
CRS,
no EPO
CRS,
EPO
Age, years 72.0 (5.9) 74 (14) 76 (11)
Male sex, n (%) 15 (75) 11 (73) 20 (67)
Body mass index, kg/m
2 23.362.3 2764* 2664*
Systolic blood pressure, mm Hg 127620 124621 125618
Diastolic blood pressure, mm Hg 79696 7 610* 6569*
Plasma total cholesterol, mmol/l 4.860.9 4.561.2 4.061.1*
HDL cholesterol, mmol/l 1.460.4 1.060.2* 1.360.3
LDL cholesterol, mmol/l 3.160.7 2.660.8 2.160.9*
Haemoglobin, mmol/l 8.6 (0.7) 7.4 (0.6)* 7.3 (1.1)*
Serum EPO level, IU/l NA 11.566.8 11.966.0
Estimated creatinine clearance,
ml/min
66 (22) 30 (31)* 31 (25)*
Serum urea, mmol/l 5.1 (2.3) 12.2 (9.5)* 16.0 (10.6)*
NT-proBNP, pg/ml NA 1680 (2132) 2064 (3155)
Ejection fraction, % NA 46613 43614
Aetiology CHF, n ischaemic/
hypertensive/valvular/other
e 11/2/2/0 17/4/3/6
hsCRP, mg/l 1.04 (2.53) 4.59 (7.90) 5.77 (9.14)
Diabetes mellitus, n (%) 0 4 (27) 10 (33)
Smoker, n (%) 6 (30) 3 (20) 2 (7)
Medication, n (%)
Statin 0 10 (67) 21 (70)
Angiotensin blocker 0 14 (93) 27 (90)
Beta blocker 0 9 (60) 20 (67)
Aldactone 0 4 (27) 8 (27)
Endothelial dysfunction parameters
ICAM-1, ng/ml 213 (56) 284 (124) 336 (226)*
VCAM-1, ng/ml 23.3 (4.5) 97 (80)* 103 (56)*
Thrombomodulin, ng/ml <0.01 (0.15) 1.1 (1.2)* 0.9 (1.7)*
eSelectin, ng/ml 3.3260.81 4.2261.76 4.1361.23
Values are presented as n (number) (%), mean6SD or median (IQR).
*ANOVA test: p <0.05 compared to healthy controls; no statistical differences were found
between CRS patients in EPO versus no EPO group. NA, not available; CRS, cardiorenal
syndrome; HDL/LDL, high/low density lipoprotein; hsCRP, high sensitive C reactive protein;
NT-proBNP, N-terminal Pro B-type natriuretic peptide; ICAM-1, intercellular adhesion
molecule-1; VCAM-1, vascular cell adhesion molecule-1.
Figure 1 Progenitor cell levels and
function in patients with cardiorenal
syndrome (CRS) compared to healthy
controls. Comparison of circulating
CD34
+KDR
+-cell levels (A), CD34
+-cell
levels (B), cultured endothelial
progenitor cell (EPC) number (C) and
function as determined by scratch
wound analysis (D) between CRS
patients (n¼45) and healthy controls
(n¼20). NC, negative control.
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Cardiorenal syndromeprogenitor cell counts. CD34
+-cell levels tended to correlate
negatively with all levels of measured endothelial dysfunction
parameters at baseline. Reduced CD34
+KDR
+-cell levels were
also associated with increased VCAM-1 levels, but not with
other endothelial dysfunction measures (supplementary table).
EPC outgrowth level and function were not associated with any
of the markers.
SDF-1a levels were signiﬁcantly enhanced in CRS patients
versus controls (3.1 (0.8) vs 2.6 (0.3) pg/ml; p¼0.001). SDF-1a
levels correlated with estimated creatinine clearance (r¼ 0.361;
p¼0.004), serum urea (r¼0.527; p<0.001), Hb (r¼ 0.276;
p¼0.03) and NT-proBNP (r¼0.503; p¼0.001), but not with
ejection fraction (r¼ 0.190; p¼0.307). SDF-1a levels increased
with deterioration of endothelial dysfunction measured by
ICAM-1 (r¼0.437; p¼0.002), VCAM-1 (r¼0.553; p<0.001) and
thrombomodulin (r¼0.494; p<0.001), but not with eSelectin
(r¼0.203; p¼0.162). ICAM-1 (b¼0.313; 95% CI 0.000 to
0.002; p¼0.041) and VCAM-1 (b¼0.441; 95% CI 1.888 to
9.813; p¼0.005) remained independent predictors of SDF-1a
in multivariate regression analysis for signiﬁcant univariate
determinants.
We observed no relation between levels of circulating
CD34
+KDR
+-cells and SDF-1a levels in the total patient
population (r¼0.127; p¼0.352). However, SDF-1a was corre-
lated with CD34
+KDR
+-cells in patients with milder CHF
indicated by low levels (below median) of NT-proBNP (r¼0.469;
p¼0.05) or high (above median) ejection fraction (r¼0.651;
p¼0.022). Correlations were absent or even reversed in more
severe CHF (r¼0.104; p¼0.661 in patients with NT-proBNP
levels above median, and r¼ 0.461; p¼0.083 in patients with
ejection fraction below median). SDF-1a and CD34
+KDR
+-cell
correlations were absent in patients above as well as below
median estimated creatinine clearance. Levels of VEGF were not
different between CRS patients and controls (24.8 (16.4) vs 22.5
(7.1) pg/ml; p¼0.212).
Short-term EPO treatment has no effect on EPC in CRS patients
Short-term (18 days) EPO had no effect on levels of CD34
+-
or CD34
+KDR
+-cells, EPC outgrowth and migratory function as
compared tobaseline (ﬁgure 2).Progenitorcell levels andfunction
also did not signiﬁcantly change in the non EPO-treated group as
compared to baseline. No signiﬁcant differences in CD34
+- and
CD34
+KDR
+-cells, and EPC outgrowth and function were
observed between the EPO-treated and non EPO-treated group.
Long-term EPO treatment prevents a decline in EPC in CRS
patients
Long-term (52 weeks) EPO did not alter CD34
+KDR
+-EPC,
CD34
+-HSC levels, EPC outgrowth or function compared to
baseline. In patients not treated with EPO a signiﬁcant decline
in CD34
+KDR
+-EPC was found after 52 weeks (ﬁgure 3A).
CD34
+KDR
+-EPC tended to be lower in patients without EPO
therapy after 52 weeks compared to those who received EPO
therapy (p¼0.077), whereas levels were not different between
the groups at baseline (p¼0.437). No differences in CD34
+-HSC,
EPC outgrowth and function were observed in the group
without EPO treatment after 52 weeks as compared to baseline
(ﬁgure 3BeD).
DISCUSSION
The present data show that patients with CRS and anaemia
who receive standard medication have reduced levels of circu-
lating CD34
+KDR
+-EPC, despite increased levels of progenitor
cell mobilising factor SDF-1a. We observed no effect of short-
term, 18 days EPO therapy on EPC levels. In cardiorenal patients
not treated with EPO, we observed a marked reduction in
CD34
+KDR
+-EPC levels after one year compared to baseline.
Long-term, 52 weeks EPO therapy did not signiﬁcantly affect
this reduction in CD34
+KDR
+-EPC levels.
Our study is the ﬁrst to report reduced circulating progenitor
cells in patients with CRS. Studies on circulating EPC in
patients with CHF report variable results.
6 72 12 2We observed
that in the presence of CHF, CKD and anaemia, CD34
+KDR
+-
cell levels were decreased independent of cardiac disease severity,
as assessed by ejection fraction or NT-proBNP levels. Plasma
levels of NT-proBNP may be inﬂuenced by renal dysfunction,
but remain a powerful reﬂection of cardiac status.
23 At tissue
level EPC recruitment depends on ischaemia or endothelial
injury induced up-regulation of SDF-1a. In our study, SDF-1a
levels correlated with renal function, heart function and endo-
thelial dysfunction markers, indicating that signals for
Figure 2 Short-term effects of
erythropoietin (EPO) treatment on
circulating endothelial progenitor cell
(EPC) in patients with cardiorenal
syndrome (CRS). Comparison of
circulating CD34+KDR+-cell levels (A),
CD34+-cell levels (B), cultured EPC
number (C) and function as determined
by scratch wound analysis (D) between
CRS patients treated with EPO for
18 days (n¼30, open bars) and
non-EPO treated patients (n¼15,
ﬁlled bars).
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Cardiorenal syndromeprogenitor cell mobilisation are intact. However, this did not
result in an efﬁcient EPC increase in CRS. This may be explained
by impaired EPC production due to uraemia and other cardio-
vascular risk factors and/or increased homing to injured endo-
thelium. In agreement with previous results,
7 in CRS patients
with mild CHF, increased SDF-1a levels were associated with
higher CD34
+KDR
+-EPC levels, suggesting that in milder CHF
stages SDF-1a can lead to EPC mobilisation. In contrast, in
severe CHF the association between SDF-1a and EPC levels
disappeared or even reversed, suggesting an impaired EPC
mobilising response to SDF-1a in this stage. This is consistent
with the biphasic response reported in severe CHF
67and may
relate to exhaustion of haematopoietic progenitors at the BM
level or inﬂammatory factors exerting BM suppression in
advanced CHF.
7 Indeed, our data show a signiﬁcant inverse
relation between IL-6 levels and CD34
+-HSC numbers. Inﬂam-
matory cytokines are known to exert a suppressive effect on
erythropoiesis. Consistently, in our patients with mild anaemia
we observed lower Hb levels when hsCRP levels were higher. We
observed no correlations between serum EPO levels and either
Hb levels or endothelial progenitor cell counts. Interestingly,
CD34
+KDR
+-EPC levels correlated positively with Hb levels,
suggesting a common BM suppressive effect on both EPC
production or mobilisation and erythropoiesis.
In our study short-term EPO administration did not inﬂuence
HSC or EPC levels. This contrasts with previous reports in CKD
or post-myocardial infarction patients.
8 12 In part this discrep-
ancy may be explained by differences in EPO dosage, as EPC
response to EPO has been shown to be dose-dependent.
24 Since
the potential clinical problems caused by long-term EPO are
presumably dose-related,
25 our patients received a relatively low,
currently recommended, EPO dosage (50 IU/kg/week). This was
sufﬁcient to enhance reticulocyte levels. It could be that our CRS
patients were not able to increase EPC levels in response to EPO
due to exhaustion or suppression of these progenitors at the BM
level.
72 6In line with this hyporesponsiveness of EPC on EPO,
we observed no relations between serum EPO and EPC levels,
whereas endogenous EPO levels were reported to be positively
associated with EPC levels in CHF
27 or CKD.
28
To our knowledge, no previous randomised trials have
reported on one-year follow-up of EPC or HSC levels in a high
CVD risk population. In patients not treated with EPO, we
observed a 68% reduction in CD34
+KDR
+-EPC levels after one
year compared to baseline, whereas HSC levels remained
unchanged compared to baseline. This discrepancy may be
related to the fact that CRS is associated with impaired NO
availability, and that NO and the NO producing enzyme eNOS
are essential for EPC mobilisation.
29 Our ﬁnding that EPC
reduced over time whereas HSC were not affected seems
consistent with the observation that NO supported mobi-
lisation of EPC but not of HSC in a mouse model.
30 Long-term
EPO treatment showed a minor and non-signiﬁcant effect on
preserving EPC levels over one year. One previous study reported
no difference in EPC levels between EPO and non-EPO treated
CHF patients after 2.5 years follow-up. However, this observa-
tion may be confounded by the cross-sectional study design and
retrospective matching of the control group.
13
In contrast to circulating CD34
+KDR
+-EPC, EPC outgrowth
and function were not different between CRS patients and
controls. It could be that CRS affects mainly the ‘true’ progen-
itor cells in the haematopoietic/endothelial lineage as it affects
progenitors in the erythropoietic lineage in BM. CD34
+KDR
+-
EPC represent a deﬁned subset of true BM-derived progenitor
cells with the ability for clonal expansion into endothelial cell
colonies from single cells.
31 Cultured EPC are mostly derived
from CD34-negative cells, and can adopt an endothelial
phenotype after culture, but are not able to clonally expand.
Earlier studies reported decreased EPC outgrowth and colony
forming units in CHF
572 6or CKD.
32 Besides study population
differences, differences in culture method may contribute to the
observed discordances.
571 33 2However, our methodology is
the same as in previous studies in which we found reduced
CD34
+KDR
+-EPC and EPC outgrowth in patients with CKD
20
and ESRD,
3 and comparable to methods used in articles
reporting reduced cultured EPC in CHF
26 and CKD.
33
In conclusion, CRS patients showed reduced CD34
+KDR
+-
EPC levels, consistent with a reduced vascular regenerative
potential and despite increased SDF-1a levels. Over a one-year
follow-up period a marked 68% further reduction in EPC levels
was observed in the patient group without EPO treatment. In
spite of promising experimental studies, our longitudinal, rand-
omised study did not show signiﬁcant inﬂuence of either short-
or long-term EPO therapy on reduced EPC levels in CRS
patients.
Figure 3 Long-term effects of
erythropoietin (EPO) treatment on
circulating endothelial progenitor cell
(EPC) in patients with cardiorenal
syndrome (CRS). Comparison of
circulating CD34+KDR+-cell levels (A),
CD34+-cell levels (B), cultured EPC
number (C) and function as determined
by scratch wound analysis (D) between
CRS patients treated with EPO for
52 weeks (n¼13, open bars) and
non-EPO treated patients (n¼13,
ﬁlled bars).
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